BiotechTube

Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel

ApprovedActive
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Keratosis, Actinic

Conditions

Keratosis, Actinic

Trial Timeline

Oct 24, 2022 → Jul 1, 2027

NCT ID
NCT05387525

About Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel

Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel is a approved stage product being developed by Almirall for Keratosis, Actinic. The current trial status is active. This product is registered under clinical trial identifier NCT05387525. Target conditions include Keratosis, Actinic.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05387525ApprovedActive

Competing Products

20 competing products in Keratosis, Actinic

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
Investigational Treatment + Active comparatorNovartisPhase 2
52
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
Imiquimod + DiclofenacViatrisApproved
82
Imiquimod 5 % CreamViatrisPhase 2
49
Aldara (Imiquimod)ViatrisPhase 3
74
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80
LAS41005AlmirallPhase 2
47
Cryotherapy + TirbanibulinAlmirallPhase 3
72
TirbanibulinAlmirallPhase 3
72

Other Products from Almirall

TildrakizumabApproved
80
Tiotropium + AclidiniumApproved
80
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved
80
Pidotimod + PlaceboApproved
80
lebrikizumabApproved
80